Vir Biotechnology, Inc. (VIR) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Vir Biotechnology reported revenue of $68.6M, down 7.6% from $74.2M the year before. Net income was -$438.0M (a -638.9% net margin), or -$3.16 per diluted share. Gross margin was 100.0% and operating margin was -699.2%. Operating activities generated -$391.8M of cash, leaving -$396.6M of free cash flow. At fiscal year end, Vir Biotechnology held $1.00B in total assets against $237.5M in total liabilities, including $232.2M of cash and equivalents.
Open the full interactive Vir Biotechnology financials → Quarterly statements, key ratios, valuation history and price charts.
Vir Biotechnology Key Stats
| Share Price | $10.61 |
|---|---|
| Market Cap | $1.79B |
| Revenue YoY Growth | -7.6% |
| 52-Week Range | $5.12 – $11.78 |
| Shares Outstanding | 167.7 million (basic, 2026 Q2) |
Vir Biotechnology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $76.4M | $1.10B | $1.62B | $86.2M | $74.2M | $68.6M |
| Cost of Goods Sold | — | $674.7M | $782.7M | $770.5M | $661.4M | $547.9M |
| Gross Profit | — | $1.03B | $1.47B | $83.4M | $73.4M | $68.5M |
| Operating Income | -$297.0M | $420.8M | $833.1M | -$684.3M | -$587.2M | -$479.3M |
| Pre-Tax Income | -$298.6M | $549.8M | $754.3M | -$628.2M | -$523.1M | -$437.8M |
| Income Tax | $54,000 | $21.2M | $238.4M | -$13.1M | -$1.1M | $217,000 |
| Net Income | -$298.7M | $528.6M | $515.8M | -$615.1M | -$522.0M | -$438.0M |
| Diluted EPS | -$0.83 | $3.96 | $3.83 | -$4.59 | -$3.83 | -$3.16 |
Vir Biotechnology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $240,000 | $64.1M | -$29,000 | $238.9M |
| Net Income | -$163.1M | -$42.9M | -$125.7M | $80.1M |
| Diluted EPS | -$1.17 | -$0.31 | -$0.85 | $0.47 |
Vir Biotechnology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $436.6M | $347.8M | $848.6M | $241.6M | $222.9M | $232.2M |
| Current Assets | $772.4M | $1.56B | $2.52B | $1.59B | $1.04B | $514.1M |
| Total Assets | $918.8M | $1.95B | $2.80B | $1.92B | $1.40B | $1.00B |
| Current Liabilities | $99.1M | $341.2M | $511.0M | $175.4M | $119.7M | $92.8M |
| Total Liabilities | $201.9M | $522.4M | $724.1M | $328.8M | $248.4M | $237.5M |
| Shareholders' Equity | $716.9M | $1.43B | $2.08B | $1.59B | $1.15B | $765.3M |
Vir Biotechnology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$190.9M | -$47.6M | $1.66B | -$778.8M | -$446.4M | -$391.8M |
| Cash From Investing | -$9.9M | -$140.8M | -$1.19B | $164.6M | $499.4M | $310.4M |
| Cash From Financing | $529.5M | $100.3M | $34.8M | $7.5M | $4.4M | $3.8M |
| Free Cash Flow | -$197.5M | -$69.4M | $1.60B | -$800.4M | -$453.7M | -$396.6M |
Figures from Vir Biotechnology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Vir Biotechnology financials page for every line item.
Vir Biotechnology Company Profile
| Ticker | VIR |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001706431 |
Frequently Asked Questions
What was Vir Biotechnology's revenue in fiscal 2025?
Vir Biotechnology (VIR) reported revenue of $68.6M for fiscal 2025.
What is Vir Biotechnology's annual revenue history?
Vir Biotechnology's annual revenue by fiscal year: 2020: $76.4M; 2021: $1.10B; 2022: $1.62B; 2023: $86.2M; 2024: $74.2M; 2025: $68.6M.
What was Vir Biotechnology's net income in fiscal 2025?
Vir Biotechnology reported net income of -$438.0M for fiscal 2025.
What was Vir Biotechnology's earnings per share (EPS) in fiscal 2025?
Vir Biotechnology's diluted EPS was -$3.16 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Vir Biotechnology generate in fiscal 2025?
Vir Biotechnology generated -$396.6M of free cash flow in fiscal 2025.
What was Vir Biotechnology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Vir Biotechnology reported revenue of $238.9M.
How many shares of Vir Biotechnology are outstanding?
Vir Biotechnology reported a weighted average of 167.7 million basic shares outstanding in 2026 Q2.
What is Vir Biotechnology's market cap?
Based on its latest closing price, Vir Biotechnology (VIR) has a market capitalization of about $1.79B.
When does Vir Biotechnology's fiscal year end?
Vir Biotechnology's fiscal year end, as registered with the SEC, is December 31.
Where is Vir Biotechnology headquartered?
Vir Biotechnology lists its business address in San Francisco, California in its SEC filings.
Vir Biotechnology Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →